Discovery of MK-1462: GLP-1 and Glucagon Receptor Dual Agonist for the Treatment of Obesity and Diabetes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Discovery of MK-1462: GLP-1 and Glucagon Receptor Dual Agonist for the Treatment of Obesity and Diabetes

Published:2022-07-21 Issue:8 Volume:13 Page:1248-1254
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Palani Anandan¹^ORCID,Nawrocki Andrea R.¹,Orvieto Federica²,Bianchi Elisabetta²^ORCID,Mandić Emanuela²,Pessi Antonello³,Huang Chunhui¹^ORCID,Deng Qiaolin¹^ORCID,Toussaint Nathalie¹,Walsh Erika¹,Reddy Vijay¹,Ashley Eric¹^ORCID,He Huaibing¹,Mumick Sheena¹,Hawes Brian¹,Marsh Donald¹,Erion Mark¹,Nargund Ravi¹,Carrington Paul E.¹

Affiliation:

1. Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033 United States,

2. Peptide Chemistry Unit, Peptides and Small Molecules R&D, IRBM SpA, Via Pontina, Km 30.600, 00071 Roma, Italy

3. PeptiPharma, Viale Citta D’Europa 679, 00144 Roma, Italy

Funder

Merck Sharp and Dohme

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.2c00217

Reference26 articles.

1. Anti-obesity drug discovery: advances and challenges

2. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes

3. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

4. Potential side effects to GLP-1 agonists: understanding their safety and tolerability

5. Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article;Indian Journal of Endocrinology and Metabolism;2024-09-04

2. Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes;Diabetes Therapy;2024-04-04

3. The molecular pharmacology of glucagon agonists in diabetes and obesity;Peptides;2023-07

4. Discovery of Insulin/GLP-1/Glucagon Triagonists for the Treatment of Diabetes and Obesity;ACS Medicinal Chemistry Letters;2022-07-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3